CoraVax™ COVID-19 Vaccine

CoraVax™ vaccine is made from the spike protein component of the SARS-CoV-2 coronavirus. CoraVax utilizes a killed rabies vaccine with the spike protein as an added component. The rabies vaccine is known to produce a strong immune response and has been proven safe for populations, including children and pregnant women. An individual vaccinated with Coravax will likely develop antibodies for SARS-CoV-2 and rabies. In viral challenge experiments, animals given CoraVax were fully protected against disease, while all control animals showed infection at the expected levels. CORAVAX is a promising dual-antigen vaccine candidate for clinical evaluation against SARS-CoV-2 and Rabies virus.

Bharat Biotech partnered with the Pennsylvania-based Thomas Jefferson University to develop Coravax.

CoraVax Vaccine Indication

Coravax is indicated for preventing the SARS-CoV-2 virus, which causes COVID-19.

CoraVax Vaccine News

October 16, 2020 - Rabies virus-based COVID-19 vaccine CORAVAX™ induces high levels of neutralizing antibodies against SARS-CoV-2. The results presented in this preclinical study indicate that CORAVAX is an excellent candidate vaccine against COVID-19.

August 28, 2020—Thomas Jefferson University received a $508,000 award and the required matching funds from partner Bharat Biotech and The Philadelphia Foundation for the development of CoraVax™. 

May 20, 2020 - Thomas Jefferson University of Philadelphia has signed an exclusive deal to develop a new vaccine, COVID-19 vaccine candidates, Jefferson. The novel vaccine was developed using an existing deactivated rabies vaccine as a vehicle for coronavirus proteins.

April 7, 2020 - Researchers at the Jefferson Vaccine Center at Thomas Jefferson University announced they have a COVID-19 vaccine candidate that could cover a global need. “Our vaccine candidate, CORAVAX™, is made from part of the current coronavirus, and that is combined with another proven vaccine that serves as a carrier of sorts,” says Matthias Schnell, Ph.D., Director of the Jefferson Vaccine Center. “The benefit is that the ‘carrier’ vaccine has already been rigorously tested and proven safe and effective. There are manufacturing plants worldwide already that have ning and with the technological know-how to produce large quantities of that vaccine. We can leverage that efficiency and safety record.”